Precision Medicine

With its burn treatment gaining traction and a pivotal wound care drug in late-stage trials, MediWound prepares to make its case to Wall Street.

NRx Pharmaceuticals gets a green light from the FDA to seek broader approval for its ketamine drug, NRX-100, using a novel real-world evidence approach.

A new health tech company has assembled a star-studded scientific board to back its AI-powered dementia prevention app. But can it deliver on its promise?

With a bolstered cash runway from recent funding, Inventiva is all-in on its MASH drug, lanifibranor, racing against giants in a multi-billion dollar market.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.

A new genomics tracker reveals the fragmented adoption of precision cancer care across the EU-5, highlighting critical barriers and strategic opportunities.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

Dr. Batra's launches XODerma, a high-tech exosome skin therapy in Dubai, blending homeopathy with cellular science. But does the hype outpace regulation?

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

Aethlon Medical advances its Hemopurifier for oncology and Long COVID, but a shrinking cash reserve and rising quarterly loss test its lean science strategy.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

DifGen Pharmaceuticals' new FDA-approved generic eye drop is only the second of its kind, promising to increase competition and lower costs for patients.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.

Clinical-stage biotech BioVie announces its novel anti-inflammatory drug, bezisterim, will be featured at a key psychiatric conference for its potential.

A new diagnostic tool for interstitial lung disease receives FDA Fast Track, promising earlier, more accurate detection of deadly lung inflammation.

With over $10M in new funding, Berlin Heals is advancing a novel implant that uses a gentle electrical field to potentially reverse heart failure damage.

A new drug, JIN-A02, shows early promise in overcoming resistance to common lung cancer therapies, even shrinking hard-to-treat brain metastases.

The French biopharma giant posts strong 2025 results and forecasts over 13% growth, fueled by a booming pipeline and unexpected market advantages.